Iovance Biotherapeutics (IOVA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $32.00 price target.
Joseph Pantginis has given his Buy rating due to a combination of factors including Iovance Biotherapeutics’ strong financial performance and promising clinical advancements. The company’s reported revenue for both the fourth quarter and full year of 2024 exceeded expectations, indicating robust demand for their products, AMTAGVI and Proleukin. Additionally, Iovance has reiterated its revenue guidance for 2025, suggesting confidence in continued growth.
Moreover, the company’s progress in clinical trials, particularly in the area of tumor-infiltrating lymphocytes (TILs), is noteworthy. Iovance is making strides in addressing unmet medical needs in endometrial cancer, with ongoing trials and anticipated data releases. The development of next-generation TIL assets and advancements in related therapies further bolster the company’s potential for future success. These factors collectively support Pantginis’s optimistic outlook and Buy rating for Iovance Biotherapeutics.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $18.00 price target.